Sun Pharma to buy 16.7 percent stake in Lyndra Therapeutics for Rs 249 crore

The transaction is expected to be completed by the end of December 2023, subject to certain conditions, Sun Pharma added.

Published On 2023-12-19 09:14 GMT   |   Update On 2023-12-21 05:41 GMT

Mumbai: India's Sun Pharmaceuticals Ltd has announced that it has entered into agreement to acquire a 16.7 per cent stake in US company Lyndra Therapeutics Inc for USD 30 million.Lyndra Theraputics, based in Massachusetts, is engaged in the business of developing novel delivery technology for long-acting oral (LAO) therapies.Sun Pharma stated in a regulatory filing that it is making the...

Login or Register to read the full article

Mumbai: India's Sun Pharmaceuticals Ltd has announced that it has entered into agreement to acquire a 16.7 per cent stake in US company Lyndra Therapeutics Inc for USD 30 million.

Lyndra Theraputics, based in Massachusetts, is engaged in the business of developing novel delivery technology for long-acting oral (LAO) therapies.

Sun Pharma stated in a regulatory filing that it is making the strategic investment to support development of innovative pharmaceutical delivery technologies and get access to the technology for certain molecules and territories.

The transaction is expected to be completed by the end of December 2023, subject to certain conditions, it added.

Lyndra was founded in 2015 with technology that emerged from the Langer Lab at MIT. The company clocked a turnover of $10.7 million in 2022

Read also: Sun Pharma gets CDSCO panel nod to manufacture, and market Etifoxine HCL capsules for anxiety

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.

Read also: Sun Pharma Ilumetri now included in category B of China National Reimbursement Drug List

Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News